Cytokinetics Ownership | Who Owns Cytokinetics?
Cytokinetics Ownership Summary
Cytokinetics is owned by 131.25% institutional investors, 0.65% insiders. Blackrock funding, inc. /de is the largest institutional shareholder, holding 15.93% of CYTK shares. T. Rowe Price Capital Appreciation is the top mutual fund, with 4.52% of its assets in Cytokinetics shares.
CYTK Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Cytokinetics | 131.25% | 0.65% | -31.90% |
| Sector | Healthcare Stocks | 247.07% | 12.15% | -159.22% |
| Industry | Biotech Stocks | 385.89% | 11.79% | -297.68% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 21.04M | 15.93% | $1.39B |
| T. rowe price investment management | 18.72M | 15.18% | $1.59B |
| Blackrock | 14.67M | 14.40% | $794.97M |
| Vanguard group | 12.05M | 10.04% | $765.54M |
| Wellington management group llp | 6.93M | 5.62% | $590.52M |
| State street | 7.14M | 5.41% | $470.81M |
| Vanguard portfolio management | 6.80M | 5.15% | $448.16M |
| Vanguard capital management | 6.27M | 4.74% | $413.02M |
| Avoro capital advisors | 5.00M | 4.06% | $425.95M |
| Bank of america corp /de/ | 4.64M | 3.76% | $394.92M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Royalty pharma sub-manager | 980.39K | 32.92% | $64.62M |
| Rp management | 980.39K | 22.73% | $51.76M |
| Foresite capital management iv | 714.70K | 20.98% | $60.88M |
| Sarissa capital management lp | 228.62K | 10.95% | $19.48M |
| Checkpoint capital | 517.28K | 7.71% | $34.09M |
| Melqart asset management (uk) | 767.52K | 6.22% | $65.39M |
| Boxer capital | 2.10M | 5.99% | $113.78M |
| Integral health asset management | 1.60M | 5.38% | $136.30M |
| First turn management | 527.41K | 4.81% | $44.93M |
| Gsk | 340.43K | 4.51% | $22.44M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 14.67M | 0.02% | 2.26M |
| Invesco | 3.02M | 0.02% | 1.78M |
| Avoro capital advisors | 5.00M | 3.82% | 1.67M |
| Bank of america corp /de/ | 4.64M | 0.03% | 1.51M |
| T. rowe price investment management | 18.72M | 1.05% | 1.19M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Darwin global management | - | - | -4.58M |
| Fmr | 2.23M | 0.01% | -2.81M |
| Sixth street partners management company | - | - | -1.57M |
| Paradigm biocapital advisors lp | - | - | -1.48M |
| Westfield capital management co lp | - | - | -1.31M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Holocene advisors, lp | 1.14M | 0.22% | 1.14M | $97.51M |
| Norges bank | 1.02M | 0.01% | 1.02M | $86.51M |
| Wcm investment management | 910.49K | 0.10% | 910.49K | $59.76M |
| Vaughan nelson investment management | 661.16K | 0.45% | 661.16K | $43.58M |
| Jump financial | 220.85K | 0.10% | 220.85K | $14.56M |
Sold Out
| Holder | Change |
|---|---|
| Stone house investment management | -1.00 |
| New england capital financial advisors | -1.00 |
| Plante moran financial advisors | -1.00 |
| Financial gravity asset management | -2.00 |
| Strategic advocates | -2.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | 507 | 3.05% | 161,798,316 | 10.76% | 131 | 0.92% | 333 | 28.57% | 103 | -26.43% |
| Mar 31, 2026 | 258 | -45.45% | 51,788,965 | -62.86% | 43 | 0.32% | 147 | -42.35% | 69 | -46.92% |
| Dec 31, 2025 | 328 | -22.64% | 72,535,010 | -48.66% | 60 | 0.43% | 182 | -19.82% | 87 | -18.69% |
| Sep 30, 2025 | 403 | 16.47% | 144,458,231 | 4.66% | 120 | 0.91% | 217 | 25.43% | 105 | -0.94% |
| Jun 30, 2025 | 344 | -10.88% | 137,969,518 | 1.88% | 115 | 0.88% | 171 | -14.50% | 106 | -0.93% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Capital Appreciation | 6.29M | 4.52% | - |
| Vanguard Health Care Inv | 5.69M | 4.09% | 2.58M |
| iShares Core S&P Mid-Cap ETF | 5.00M | 3.59% | 2.68K |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.45M | 3.20% | 124.03K |
| Vanguard Total Stock Mkt Idx Inv | 4.32M | 3.18% | 30.41K |
| Vanguard Morn Total Stk Mkt Idx Investor | 4.32M | 3.18% | 30.41K |
| Vanguard US Total Market Shares ETF | 3.75M | 3.15% | 128.42K |
| iShares Russell 2000 ETF | 3.42M | 2.46% | - |
| Vanguard Small Cap Index | 3.13M | 2.25% | 5.32K |
| American Funds SMALLCAP World A | 2.62M | 1.89% | -372.10K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Nov 09, 2026 | PARSHALL B LYNNE | - | Sell | $141.19K |
| Nov 09, 2026 | PARSHALL B LYNNE | - | Sell | $132.45K |
| Nov 03, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | $220.25K |
| Nov 02, 2026 | Blum Robert I | President & CEO | Sell | $471.07K |
| Oct 20, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | $224.03K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q4 | - | 5 |
| 2026 Q3 | - | 20 |
| 2026 Q2 | - | 25 |
| 2026 Q1 | - | 22 |
| 2025 Q4 | - | 20 |
CYTK Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools